RA 9165 (Dangerous Drug Act)
RA 9165 (Dangerous Drug Act)
RA 9165 (Dangerous Drug Act)
SECTION 1. Short Title . — This Act shall be known and cited as the
"Comprehensive Dangerous Drugs Act of 2002". DHITcS
(4) After the filing of the criminal case, the Court shall, within
seventy-two (72) hours, conduct an ocular inspection of the
confiscated, seized and/or surrendered dangerous drugs,
plant sources of dangerous drugs, and controlled precursors
and essential chemicals, including the
instruments/paraphernalia and/or laboratory equipment, and
through the PDEA shall within twenty-four (24) hours
thereafter proceed with the destruction or burning of the
same, in the presence of the accused or the person/s from
whom such items were confiscated and/or seized, or his/her
representative or counsel, a representative from the media
and the DOJ, civil society groups and any elected public
official. The Board shall draw up the guidelines on the
manner of proper disposition and destruction of such item/s
which shall be borne by the offender: Provided, That those
item/s of lawful commerce, as determined by the Board, shall
be donated, used or recycled for legitimate purposes:
Provided, further, That a representative sample, duly
weighed and recorded is retained;
(e) Officers and members of the military, police and other law
enforcement agencies. — Officers and members of the
military, police and other law enforcement agencies shall
undergo an annual mandatory drug test;
A certified true copy of such record covering a period of six (6) months,
duly signed by the pharmacist or the owner of the drugstore, pharmacy or
chemical establishment, shall be forwarded to the Board within fifteen (15)
CD Technologies Asia, Inc. © 2021 cdasiaonline.com
days following the last day of June and December of each year, with a copy
thereof furnished the city or municipal health officer concerned.
(b) A physician, dentist, veterinarian or practitioner authorized to
prescribe any dangerous drug shall issue the prescription therefor in one (1)
original and two (2) duplicate copies. The original, after the prescription has
been filled, shall be retained by the pharmacist for a period of one (1) year
from the date of sale or delivery of such drug. One (1) copy shall be retained
by the buyer or by the person to whom the drug is delivered until such drug
is consumed, while the second copy shall be retained by the person issuing
the prescription.
For purposes of this Act, all prescriptions issued by physicians, dentists,
veterinarians or practitioners shall be written on forms exclusively issued by
and obtainable from the DOH. Such forms shall be made of a special kind of
paper and shall be distributed in such quantities and contain such
information and other data as the DOH may, by rules and regulations,
require. Such forms shall only be issued by the DOH through its authorized
employees to licensed physicians, dentists, veterinarians and practitioners in
such quantities as the Board may authorize. In emergency cases, however,
as the Board may specify in the public interest, a prescription need not be
accomplished on such forms. The prescribing physician, dentist, veterinarian
or practitioner shall, within three (3) days after issuing such prescription,
inform the DOH of the same in writing. No prescription once served by the
drugstore or pharmacy be reused nor any prescription once issued be
refilled.
(c) All manufacturers, wholesalers, distributors, importers, dealers
and retailers of dangerous drugs and/or controlled precursors and essential
chemicals shall keep a record of all inventories, sales, purchases,
acquisitions and deliveries of the same as well as the names, addresses and
licenses of the persons from whom such items were purchased or acquired
or to whom such items were sold or delivered, the name and quantity of the
same and the date of the transactions. Such records may be subjected
anytime for review by the Board.
ARTICLE IV
Participation of the Family, Students, Teachers and School Authorities in the
Enforcement of this Act
SECTION 41. Involvement of the Family . — The family being the
basic unit of the Filipino society shall be primarily responsible for the
education and awareness of the members of the family on the ill effects of
dangerous drugs and close monitoring of family members who may be
susceptible to drug abuse.
SECTION 42. Student Councils and Campus Organizations. — All
elementary, secondary and tertiary schools' student councils and campus
organizations shall include in their activities a program for the prevention of
and deterrence in the use of dangerous drugs, and referral for treatment and
rehabilitation of students for drug dependence.
(1) He/she has complied with the rules and regulations of the
Center, the applicable rules and regulations of the Board,
including the after-care and follow-up program for at least
eighteen (18) months following temporary discharge from
confinement in the Center or, in the case of a dependent
placed under the care of the DOH-accredited physician, the
after-care program and follow-up schedule formulated by the
DSWD and approved by the Board: Provided, That capability-
building of local government social workers shall be
undertaken by the DSWD;
ARTICLE IX
Dangerous Drugs Board and Philippine Drug Enforcement Agency
SECTION 77. The Dangerous Drugs Board. — The Board shall be the
policy-making and strategy-formulating body in the planning and formulation
of policies and programs on drug prevention and control. It shall develop and
adopt a comprehensive, integrated, unified and balanced national drug
abuse prevention and control strategy. It shall be under the Office of the
President.
SECTION 78. Composition of the Board. — The Board shall be
composed of seventeen (17) members wherein three (3) of which are
permanent members, the other twelve (12) members shall be in an ex officio
capacity and the two (2) shall be regular members.
The three (3) permanent members, who shall possess at least seven-
year training and experience in the field of dangerous drugs and in any of
the following fields: in law, medicine, criminology, psychology or social work,
shall be appointed by the President of the Philippines. The President shall
designate a Chairman, who shall have the rank of a secretary from among
the three (3) permanent members who shall serve for six (6) years. Of the
two (2) other members, who shall both have the rank of undersecretary, one
(1) shall serve for four (4) years and the other for two (2) years. Thereafter,
the persons appointed to succeed such members shall hold office for a term
of six (6) years and until their successors shall have been duly appointed and
qualified.
The other twelve (12) members who shall be ex officio members of the
Board are the following:
Cabinet secretaries who are members of the Board may designate their
duly authorized and permanent representatives whose ranks shall in no case
be lower than undersecretary.
The two (2) regular members shall be as follows:
The Director of the NBI and the Chief of the PNP shall be the
permanent consultants of the Board, and shall attend all the meetings of the
Board.
All members of the Board as well as its permanent consultants shall
receive a per diem for every meeting actually attended subject to the
pertinent budgetary laws, rules and regulations on compensation, honoraria
and allowances: Provided, That where the representative of an ex officio
member or of the permanent consultant of the Board attends a meeting in
behalf of the latter, such representative shall be entitled to receive the per
diem .
SECTION 79. Meetings of the Board. — The Board shall meet once a
week or as often as necessary at the discretion of the Chairman or at the call
of any four (4) other members. The presence of nine (9) members shall
constitute a quorum.
SECTION 80. Secretariat of the Board. — The Board shall
recommend to the President of the Philippines the appointment of an
Executive Director, with the rank of an undersecretary, who shall be the
CD Technologies Asia, Inc. © 2021 cdasiaonline.com
Secretary of the Board and administrative officer of its secretariat, and shall
perform such other duties that may be assigned to him/her. He/she must
possess adequate knowledge, training and experience in the field of
dangerous drugs, and in any of the following fields: law enforcement, law,
medicine, criminology, psychology or social work.
Two deputies executive director, for administration and operations,
with the ranks of assistant secretary, shall be appointed by the President
upon recommendation of the Board. They shall possess the same
qualifications as those of the executive director. They shall receive a salary
corresponding to their position as prescribed by the Salary Standardization
Law as a Career Service Officer.
The existing secretariat of the Board shall be under the administrative
control and supervision of the Executive Director. It shall be composed of the
following divisions, namely: Policy Studies, Research and Statistics;
Preventive Education, Training and Information; Legal Affairs; and the
Administrative and Financial Management.
SECTION 81. Powers and Duties of the Board. — The Board shall:
(a) Formulate, develop and establish a comprehensive,
integrated, unified and balanced national drug use
prevention and control strategy;
The fines shall be remitted to the Board by the court imposing such
fines within thirty (30) days from the finality of its decisions or orders. The
unclaimed and forfeited prizes shall be turned over to the Board by the PCSO
within thirty (30) days after these are collected and declared forfeited.
A portion of the funds generated by the Philippine Amusement and
Gaming Corporation (PAGCOR) in the amount of Five million pesos
(P5,000,000.00) a month shall be set aside for the purpose of establishing
adequate drug rehabilitation centers in the country and also for the
maintenance and operations of such centers: Provided, That the said amount
shall be taken from the fifty percent (50%) share of the National Government
in the income of PAGCOR: Provided, further, That the said amount shall
automatically be remitted by PAGCOR to the Board. The amount shall, in
turn, be disbursed by the Dangerous Drugs Board, subject to the rules and
regulations of the Commission on Audit (COA).
The fund may be augmented by grants, donations, and endowment
from various sources, domestic or foreign, for purposes related to their
functions, subject to the existing guidelines set by the government.
SECTION 88. Management of Funds Under this Act; Annual Report
by the Board and the PDEA. — The Board shall manage the funds as it may
deem proper for the attainment of the objectives of this Act. In addition to
the periodic reports as may be required under this Act, the Chairman of the
Board shall submit to the President of the Philippines and to the presiding
officers of both houses of Congress, within fifteen (15) days from the opening
of the regular session, an annual report on the dangerous drugs situation in
the country which shall include detailed account of the programs and
projects undertaken, statistics on crimes related to dangerous drugs,
expenses incurred pursuant to the provisions of this Act, recommended
remedial legislation; if needed, and such other relevant facts as it may deem
CD Technologies Asia, Inc. © 2021 cdasiaonline.com
proper to cite.
SECTION 89. Auditing the Accounts and Expenses of the Board and
the PDEA. — All accounts and expenses of the Board and the PDEA shall be
audited by the COA or its duly authorized representative.
ARTICLE XI
Jurisdiction Over Dangerous Drugs Cases
SECTION 90. Jurisdiction. — The Supreme Court shall designate
special courts from among the existing Regional Trial Courts in each judicial
region to exclusively try and hear cases involving violations of this Act. The
number of courts designated in each judicial region shall be based on the
population and the number of cases pending in their respective jurisdiction.
The DOJ shall designate special prosecutors to exclusively handle cases
involving violations of this Act.
The preliminary investigation of cases filed under this Act shall be
terminated within a period of thirty (30) days from the date of their filing.
When the preliminary investigation is conducted by a public prosecutor
and a probable cause is established, the corresponding information shall be
filed in court within twenty-four (24) hours from the termination of the
investigation. If the preliminary investigation is conducted by a judge and a
probable cause is found to exist, the corresponding information shall be filed
by the proper prosecutor within forty-eight (48) hours from the date of
receipt of the records of the case.
Trial of the case under this Section shall be finished by the court not
later than sixty (60) days from the date of the filing of the information.
Decision on said cases shall be rendered within a period of fifteen (15) days
from the date of submission of the case for resolution.
SECTION 91. Responsibility and Liability of Law Enforcement
Agencies and Other Government Officials and Employees in Testing as
Prosecution Witnesses in Dangerous Drugs Cases. — Any member of law
enforcement agencies or any other government official and employee who,
after due notice, fails or refuses intentionally or negligently, to appear as a
witness for the prosecution in any proceedings, involving violations of this
Act, without any valid reason, shall be punished with imprisonment of not
less than twelve (12) years and one (1) day to twenty (20) years and a fine
of not less than Five hundred thousand pesos (P500,000.00), in addition to
the administrative liability he/she may be meted out by his/her immediate
superior and/or appropriate body. DSHTaC
The Board shall also take into accord the obligations and commitments
to international treaties, conventions and agreements to which the
Philippines is a signatory.
The Dangerous Drugs Board shall give notice to the general public of
the public hearing of the reclassification, addition to or removal from the list
of any drug by publishing such notice in any newspaper of general
circulation once a week for two (2) weeks.
The effect of such reclassification, addition or removal shall be as
follows:
(a) In case a dangerous drug is reclassified as precursors and
essential chemicals, the penalties for the violations of this Act
involving the two latter categories of drugs shall, in case of
conviction, be imposed in all pending criminal prosecutions;
ANNEX
4. ERGOMETRINE
5. ERGOTAMINE
6. ISOSAFROLE
7. LYSERGIC ACID
8. 3, 4-METHYLENEDIOXYPHENYL-2 PROPANONE
9. NOREPHEDRINE
10. 1-PHENYL-2-PROPANONE
11. PIPERONAL
12. POTASSIUM PERMANGANATE
13. PSEUDOEPHEDRINE
14. SAFROLE
THE SALTS OF THE SUBSTANCES LISTED IN THIS TABLE WHENEVER THE
EXISTENCE OF SUCH SALTS IS POSSIBLE
2. ANTHRANILIC ACID
3. ETHYL ETHER
4. HYDROCHLORIC ACID
5. METHYL ETHYL KETONE
6. PHENYLACETIC ACID
7. PIPERIDINE
8. SULPHURIC ACID
9. TOLUENE
THE SALTS OF THE SUBSTANCES LISTED IN THIS TABLE WHENEVER THE
EXISTENCE OF SUCH SALTS IS POSSIBLE (THE SALTS OF HYDROCHLORIC ACID
AND SULPHURIC ACID ARE SPECIFICALLY EXCLUDED)
8. Alphamethadol
9. Alpha-methylfentanyl
10. Alpha-methylthiofentanyl
11. Alphaprodine
12. Anileridine
13. Benzethidine
14. Benzylmorphine
15. Betacetylmethadol
16. Beta-hydroxyfentanyl
17. Beta-hydroxy-3-methylfentanyl
18. Betameprodine
19. Betamethadol
20. Betaprodine
21. Bezitramide
22. Cannabis and Cannabis resin and extracts and tinctures of cannabis
23. Clonitazene
24. Coca leaf
25. Cocaine
26. Codoxime
27. Concentrate of poppy straw
28. Desomorphine
29. Dextromoramide
30. Diampromide
31. Diethylthiambutene
32. Difenoxin
CD Technologies Asia, Inc. © 2021 cdasiaonline.com
33. Dihydroetorphine
34. Dihydromorphine
35. Dihydromorphine
36. Dimenoxadol
37. Dimepheptanol
38. Dimethylthiambutene
39. Dioxaphetyl butyrate
40. Diphenoxylate
41. Dipipanone
42. Drotebanol
43. Ecgonine
44. Ethylmethylthiambutene
45. Etonitazene
46. Etorphine
47. Etoxeridine
48. Fentanyl
49. Furethidine
50. Heroin
51. Hydrocodone
52. Hydromorphinol
53. Hydromorphone
54. Hydroxypethidine
55. Isomethadone
56. Ketobemidone
57. Levomethorphan
58. Levomoramide
59. Levophenacylmorphan
60. Levorphanol
61. Metazocine
62. Methadone
63. Methadone Intermediate
64. Methyldesorphine
CD Technologies Asia, Inc. © 2021 cdasiaonline.com
65. Methyldihydromorphine
66. 3-methylfentanyl
67. 3-methylthiofentanyl
68. Metopon
69. Moramide intermediate
70. Morpheridine
71. Morphine
72. Morphine methobromide
73. Morphine-N-oxide
74. MPPP
75. Myrophine
76. Nicomorphine
77. Noracymethadol
78. Norlevorphanol
79. Normethadone
80. Normorphine
81. Norpipanone
82. Opium
83. Oxycodone
84. Oxymorphone
85. Para-fluorofentanyl
86. PEPAP
87. Pethidine
88. Pethidine intermediate A
89. Pethidine intermediate B
99. Properidine
100. Racemethorphan
101. Racemoramide
102. Racemorphan
103. Remifentanil
104. Sufentanil
105. Thebacon
106. Thebaine
107. Thiofentanyl
108. Tilidine
109. Trimeperidine
* Dextromethorphan (+)-3-methoxy-N-methylmorphinan and dextrorphan
(+)-3-hydroxy-N-methylmorphinan are isomers specifically excluded from
this Schedule.
AND the isomers, unless specifically excepted, of the drugs in this
Schedule whenever the existence of such isomers is possible within the
specific chemical designation;
The esters and ethers, unless appearing in another Schedule, of the
drugs in this Schedule whenever the existence of such esters or ethers is
possible;
The salts of the drugs listed in this Schedule, including the salts of
esters, ethers and isomers as provided above whenever the existence of
such salts is possible.
8. Norcodeine
9. Pholcodine
CD Technologies Asia, Inc. © 2021 cdasiaonline.com
10. Propiram
And the isomers, unless specifically excepted, of the drugs in this
Schedule whenever the existence of such isomers is possible within the
specific chemical designation.
The salts of the drugs listed in this Schedule, including the salts of the
isomers as provided above whenever the existence of such salts is possible.
1. Preparations of : Acetyldihydrocodeine,
Codeine,
Dihydrocodeine,
Ethylmorphine,
Nicocodine,
Nicodicodine,
Norcodeine and
Pholcodine
3. Preparations of: Dextropropoxyphene for oral use containing not more than
135 milligrams of dextropropoxyphene base per dosage unit
or with a concentration of not more than 2.5 per cent in
undivided preparations, provided that such preparations do
not contain any substance controlled under the Convention
on Psychotropic Substances of 1971.
4. Preparations of: Cocaine containing not more than 0.1 per cent of cocaine
calculated as cocaine base; and
Preparations of: Opium or morphine containing not more than 0.2 per cent of
morphine calculated as anhydrous morphine base and
compounded with one or more other ingredients and in such
a way that the drug cannot be recovered by readily
applicable means or in a yield that would constitute a risk to
public health.
5. Preparations of: Difenoxin containing, per dosage unit, not more than 0.5
milligrams of difenoxin and a quantity of atropine sulfate
equivalent. to at least 5 per cent of the dose of difenoxin.
6. Preparations of: Diphenoxylate containing per dosage unit, not more than 2.5
milligrams diphenoxylate calculated as base and a quantity of
CD Technologies Asia, Inc. © 2021 cdasiaonline.com
atropine sulfate equivalent to at least 1 per cent of the dose
of diphenoxylate.
2. Acetyl- alpha-methylfentanyl
3. Alpha-methylfentanyl
4. Alpha-methylthiofentanyl
5. Beta-hydroxy-3-methylfentanyl
6. Beta-hydroxyfentanyl
7. Cannabis and Cannabis resin
8. Desomorphine
9. Etorphine
10. Heroin
11. Ketobemidone
12. 3-methylfentanyl
13. 3-methylthiofentanyl
14. MPPP
15. Para-fluorofentanyl
16. PEPAP
17. Thiofentanyl
AND the salts of the drugs listed in this Schedule whenever the
formation of such salts is possible. EICSDT
5. LEVOMETHAMPHETAMINE
6. MECLOQUALONE
7. METAMFETAMINE (METHAMPHETAMINE)
8. METHAMPHETAMINE RACEMATE
9. METHAQUALONE
10. METHYLPHENIDATE
13. SECOBARBITAL
14. DRONABINOL (delta -9-tetrahydro-cannabinol and its stereochemical
variants)
15. ZIPEPROL
16. 2C-B(4-bromo-2,5-dimethoxyphenethylamine)
4. CATHINE (+)-norpseudo-ephedrine
5. CYCLOBARBITAL
6. FLUNITRAZEPAM
7. GLUTETHIMIDE
8. PENTAZOCINE
9. PENTOBARBITAL
5. BARBITAL
6. BENZFETAMINE (benzphetamine)
7. BROMAZEPAM
8. BROTIZOLAM
9. BUTOBARBITAL
10. CAMAZEPAM
11. CHLORDIAZEPOXIDE
12. CLOBAZAM
13. CLONAZEPAM
14. CLORAZEPATE
CD Technologies Asia, Inc. © 2021 cdasiaonline.com
15. CLOTIAZEPAM
16. CLOXAZOLAM
17. DELORAZEPAM
18. DIAZEPAM
19. ESTAZOLAM
20. ETHCHLORVYNOL
21. ETHINAMATH
22. ETHYL LOFLAZEPATE
23. ETILAMFETAMINE (N-ethylamphetamine)
24. FENCAMFAMIN
25. FENPROPOREX
26. FLUDIAZEPAM
27. FLURAZEPAM
28. HALAZEPAM
29. HALOXAZOLAM
30. KETAZOLAM
31. LEFETAMINE (SPA)
32. LOPRAZOLAM
33. LORAZEPAM
34. LORMETAZEPAM
35. MAZINDOL
36. MEDAZEPAM
37. MEFENOREX
38. MEPROBAMATE
39. MESOCARB
40. METHYLPHENOBARBITAL
41. METHYLPRYLON
42. MIDAZOLAM
43. NIMETAZEPAM
44. NITRAZEPAM
45. NORDAZEPAM
46. OXAZEPAM
CD Technologies Asia, Inc. © 2021 cdasiaonline.com
47. OXAZOLAM
48. PEMOLINE
49. PHENDIMETRAZINE
50. PHENOBARBITAL
51. PHENTERMINE
52. PINAZEPAM
53. PIPRADROL
54. PRAZEPAM
55. PYROVALERONE
56. SECBUTABARBITAL
57. TE MAZEPAM
58. TETRAZEPAM
59. TRIAZOLAM